Monograph
J07AN01 - Tuberculosis, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the tuberculosis, live attenuated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated Mycobacterium bovis BCG (Bacillus Calmette-Guérin).
Therapeutic characteristics
The tuberculosis, live attenuated vaccine (BCG vaccine) is indicated for active immunization against against tuberculosis in individuals from the age of 6 weeks to 35 years.
It is administered as a single intradermal injection.
Metabolism and pharmacokinetics
The BCG vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). BCG-vaksine SSI.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
BCG vaccin 
Vacuna bcg 
bcg · bcg Anti-Tuberculosis 
bcg 
BCG-vaksine 
bcg · Szczepionka przeciwgruzlicza BCG 
Bcg 
bcg 
bcg
© NAPOS 2025